Gastrointestinal AA Amyloidosis following Recurrent SARS-CoV-2 Infection: A Case Report
- Author:
Hyung-Min PARK
1
;
Seon-Young PARK
;
Soo Jin Na CHOI
;
Myung-Giun NOH
;
Tae-bum LEE
;
Yong-wook JUNG
Author Information
- Publication Type:Case Report
- From:Yonsei Medical Journal 2023;64(8):526-529
- CountryRepublic of Korea
- Language:English
- Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with the overproduction of serum amyloid A protein, resulting in systemic AA amyloidosis. In this report, we describe a case of gastrointestinal (GI) AA amyloidosis following SARS-CoV-2 infection. A 75-year-old male presented to the emergency department with upper abdominal pain 6 weeks post kidney transplantation. He had a history of SARS-CoV-2 infection 4 weeks prior. On day 7 of hospitalization, while receiving conservative management, the patient developed symptoms of cough and fever, leading to a diagnosis of SARS-CoV-2 reinfection. The patient’s abdominal pain persisted, and hematochezia developed on day 30 of hospitalization. Esophagogastroduodenoscopy and colonoscopy revealed multiple ulcers in the stomach and colon, with histologic findings revealing the presence of amyloid A. The patient was managed conservatively and was also given remdesivir for the SARS-CoV-2 infection. His clinical symptoms subsequently improved, and endoscopic findings demonstrated improvement in multiple gastric ulcers. GI amyloidosis may be a subacute complication following SARS-CoV-2 infection in immunocompromised patients.
